Skip to main content
. 2021 Dec 16;12:778204. doi: 10.3389/fimmu.2021.778204

Figure 2.

Figure 2

Longitudinal assessment of serum sIFNAR2 levels in responder and non-responder patients. Graphs comparing serum sIFNAR2 levels at baseline and after 6 and 12 months of IFN-β therapy onset in responder (N=22) and non-responder patients (N=19). Each point represents an individual, and horizontal bars indicate the median values and interquartile ranges. Significant p-values are shown with asterisk.